Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271155 | 0.94 | P2RX3 (0.62) | P2RX3P2RX2 | |
| SCHEMBL2277555 | 0.93 | P2RX3 (0.63) | P2RX3P2RX2 | |
| SCHEMBL357228 | 0.90 | P2RX3 (0.60) | P2RX3P2RX2 | |
| SCHEMBL2276438 | 0.90 | P2RX3 (0.65) | P2RX3P2RX2 | |
| SCHEMBL2276873 | 0.88 | P2RX3 (0.59) | P2RX3P2RX2 | |
| SCHEMBL2275053 | 0.87 | P2RX3 (0.64) | P2RX3P2RX2 | |
| SCHEMBL2275278 | 0.87 | P2RX3 (0.62) | P2RX3P2RX2 | |
| SCHEMBL2276652 | 0.86 | P2RX3 (0.62) | P2RX3P2RX2 | |
| SCHEMBL2275924 | 0.86 | P2RX3 (0.64) | P2RX3P2RX2 | |
| SCHEMBL2269560 | 0.86 | P2RX3 (0.59) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989637-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-08-02 | — | — | US | claimed |
| EP-2225213-B1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2607356-A1 | Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| US-8440708-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440708-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440708-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2011-10-06 | — | — | US | disclosed |
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2011-10-06 | — | — | US | disclosed |
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2011-10-06 | — | — | US | disclosed |
| US-7989637-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989637-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989637-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.